molecular operating environment moe software version 2015 10 (Chemical Computing Group)
86
Structured Review
Chemical Computing Group
molecular operating environment moe software version 2015 10
Molecular Operating Environment Moe Software Version 2015 10, supplied by Chemical Computing Group, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/software+version+2015/environment+molecular+operating/10__1016_slash_j__jics__2026__102624-103-7-14
Average 86 stars, based on 1 article reviews
Molecular Operating Environment Moe Software Version 2015 10, supplied by Chemical Computing Group, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/software+version+2015/environment+molecular+operating/10__1016_slash_j__jics__2026__102624-103-7-14
Average 86 stars, based on 1 article reviews
molecular operating environment moe software version 2015 10 - by Bioz Stars,
2026-11
86/100 stars
Images
Related Articles
Software:Article Title: Design, Synthesis, Molecular Modeling, and Biological Evaluation of Novel Pyrimidine Derivatives as Potential Calcium Channel Blockers. Article Snippet: .. Computer-guided docking experiments were carried out using Article Title: Copper–pyrogallol complexation dynamics: Electrochemical insights and molecular docking studies for glioma treatment Article Snippet: The electrochemical behaviour of copper chloride CuCl2 and its interaction with pyrogallol were examined in order to assess their potential as glioma-targeting medications.. Cyclic voltammetry in 0.1 M KCl at 292.15 K revealed two oxidation peaks (− 0.023 V, 0.165 V) for Cu and Cu2+ and two reduction peaks (0.095 V, − 0.370 V) for Cu and metallic Cu.. Peak currents rose with increasing CuCl2 concentration. Article Title: Developing new anticancer agents: Design, synthesis, biological evaluation and in silico study of several functionalized pyrimidine-5-carbonitriles as small molecules modulators targeting breast cancer. Article Snippet: Committed to our growing effort addressed toward the development of potent anti-breast cancer candidates, new 4-hydrazinylpyrimidine-5-carbonitriles featuring a morpholinyl or piperidinyl moiety at the position-2 and derivatized with various functionalities at the hydrazinyl group were designed through structure optimization, and their antiproliferative potency against two human breast cancer (BC) cell lines, relative to the reference drug 5-FU, was evaluated.. Compounds showing remarkable cytotoxic activity versus the hormone dependent MCF-7 cell line (IC50 = 1.62 ± 0.06 μM– 9.88 ± 0.38 μM) and the non-hormone dependent MDA-MB-231 cell line (IC50 = 3.26 ± 0.14 μM–12.93 ± 0.55 μM) were further tested by multiple assays for clarification of their potential activity.. Promising derivatives revealing low damage to healthy cells were subject to enzymatic inhibitory assessment against ARO and EGFR and their activities compared to letrozole and erlotinib respectively. Article Title: Computer-Aided Construction and Evaluation of Poly-L-Lysine/Hyodeoxycholic Acid Nanoparticles for Hemorrhage and Infection Therapy. Article Snippet: .. Final conformations were processed in the Article Title: Design, synthesis, and antiproliferative efficacy of an innovative series of triazino[5,6-b]indole derivatives targeting EGFR, CD1, Hsp90, PI3K, and ERK/AKT as key molecular targets in cancer therapy. Article Snippet: The development of novel triazino[5,6-b]indole-hydrazone conjugates and triazino[5,6-b]indole-fused heterocyclic hybrids was achieved through structural optimization.. The growth-inhibitory activity of the newly synthesized derivatives was evaluated against MCF-7 and MDA-MB-231 human breast cancer cell lines, relative to the reference drug doxorubicin, by MTT assay.. According to the results obtained, the tested compounds showed significant antiproliferative activity versus MCF-7 cell line with IC50 values ranging from 1.06 + 0.05 μM to 66.58 + 0.05 μM and MDA-MB-231 cell line IC50 values ranging from 0.78 + 0.04 μM to 51.99 + 3.85 μM in comparison to doxorubicin (IC50 = 7.45 ± 0.38 μM and 2.08 ± 0.074 μM respectively), with compounds 4, 6, 7, 9, 11, and 12 exhibited valuable biological effect towards MCF-7 cells and derivatives 4, 6, 11, and 12 effective towards MDA-MB-231 cells. In Silico:Article Title: Developing new anticancer agents: Design, synthesis, biological evaluation and in silico study of several functionalized pyrimidine-5-carbonitriles as small molecules modulators targeting breast cancer. Article Snippet: Committed to our growing effort addressed toward the development of potent anti-breast cancer candidates, new 4-hydrazinylpyrimidine-5-carbonitriles featuring a morpholinyl or piperidinyl moiety at the position-2 and derivatized with various functionalities at the hydrazinyl group were designed through structure optimization, and their antiproliferative potency against two human breast cancer (BC) cell lines, relative to the reference drug 5-FU, was evaluated.. Compounds showing remarkable cytotoxic activity versus the hormone dependent MCF-7 cell line (IC50 = 1.62 ± 0.06 μM– 9.88 ± 0.38 μM) and the non-hormone dependent MDA-MB-231 cell line (IC50 = 3.26 ± 0.14 μM–12.93 ± 0.55 μM) were further tested by multiple assays for clarification of their potential activity.. Promising derivatives revealing low damage to healthy cells were subject to enzymatic inhibitory assessment against ARO and EGFR and their activities compared to letrozole and erlotinib respectively. other:Article Title: In vitro and in vivo Biological Evaluation of Newly Tacrine-Selegiline Hybrids as Multi-Target Inhibitors of Cholinesterases and Monoamine Oxidases for Alzheimer’s Disease Article Snippet: Thus, to determine the capacity of compound 7d targeting cholinesterase at the Molecular level, we selected the crystal structure of h AChE and h BuChE for conducting molecular docking studies using the Molecular Operating Environment (MOE) 2015.10 version software from the Article Title: Synthesis, in vitro, and in silico studies of new derivatives of diphenylpiperazine scaffold: A key substructure for MAO inhibition. Article Snippet: Fifteen new diphenylpiperazine hybrids were designed, synthesized and in vitro biologically evaluated against hMAOs enzymes via fluorometric method.. All of our new compounds displayed strong inhibitory activities against both two isoforms of hMAOs with IC50 range of 0.091–16.32 μM.. According to selectivity index values, all hybrids showed higher selectivity against hMAO-A over hMAO-B. Article Title: Discovery of noncovalent diaminopyrimidine-based Inhibitors for glioblastoma via a dual FAK/DNA targeting strategy. Article Snippet: Temozolomide, a widely used alkylating agent for glioblastoma treatment, faces significant challenges due to the development of resistance, which severely impacts patient survival.. This underscores the urgent need for novel strategies to overcome this barrier.. Focal adhesion kinase (FAK), an intracellular non-receptor tyrosine kinase, is highly expressed in glioblastoma cells and has been identified as a promising therapeutic target for antiglioblastoma drug development. Inhibition:Article Title: Design, synthesis, and antiproliferative efficacy of an innovative series of triazino[5,6-b]indole derivatives targeting EGFR, CD1, Hsp90, PI3K, and ERK/AKT as key molecular targets in cancer therapy. Article Snippet: The development of novel triazino[5,6-b]indole-hydrazone conjugates and triazino[5,6-b]indole-fused heterocyclic hybrids was achieved through structural optimization.. The growth-inhibitory activity of the newly synthesized derivatives was evaluated against MCF-7 and MDA-MB-231 human breast cancer cell lines, relative to the reference drug doxorubicin, by MTT assay.. According to the results obtained, the tested compounds showed significant antiproliferative activity versus MCF-7 cell line with IC50 values ranging from 1.06 + 0.05 μM to 66.58 + 0.05 μM and MDA-MB-231 cell line IC50 values ranging from 0.78 + 0.04 μM to 51.99 + 3.85 μM in comparison to doxorubicin (IC50 = 7.45 ± 0.38 μM and 2.08 ± 0.074 μM respectively), with compounds 4, 6, 7, 9, 11, and 12 exhibited valuable biological effect towards MCF-7 cells and derivatives 4, 6, 11, and 12 effective towards MDA-MB-231 cells. |